Share this article on:

Abstract 47: Guideline-Compliant Enoxaparin Doses Are Insufficient in the Majority of Plastic Surgery Patients An Examination of Enoxaparin Metabolism

Plastic and Reconstructive Surgery – Global Open: April 2016 - Volume 4 - Issue 4S - p 25
doi: 10.1097/
PRS AAPS Oral Proofs 2016

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Christopher J. Pannucci, MD, MS,* Brad Rockwell, MD,* Kory Fleming, MPH,* Maureen Ghanem, PharmD,* Arash Momeni, MD,† Jay Agarwal, MD*

From the *University of Utah, Salt Lake City, Utah; and †University of Pennsylvania, Philadelphia, Pa.

PURPOSE: Despite guideline-compliant enoxaparin prophylaxis, 1 in 25 highest risk patients has a VTE event. We examined the pharmacokinetics of standard enoxaparin doses in plastic surgery patients with an emphasis on total body surface area surgically injured (TBSI) as a predictor of enoxaparin metabolism.

METHODS: The Plastic Surgery Foundation funded this ongoing prospective interventional study, which recruited adult plastic surgery patients receiving postoperative enoxaparin (40 mg once daily). Steady-state peak and trough anti-Factor Xa (aFXa) levels, which marks enoxaparin effectiveness and safety, were drawn. Patients with out-of-range aFXa levels had real-time dose adjustment based on a written protocol.

RESULTS: Fifty-three patients have been recruited, and 39.6% had in-range peak aFXa levels. A total of 61.5% of patients had nondetectable aFXa 12 hour trough levels. Patients with increased TBSI were less likely to have in-range aFXa peak and trough levels. Among out-of-range patients who received dose adjustment, 58.3% achieved in-range peak aFXa levels.

CONCLUSIONS: Enoxaparin 40 mg once daily provides adequate prophylaxis in less than 40% of patients. A total of 61.5% of patients had nondetectable aFXa levels at 12 hours. Thus, the majority of patients are protected for less than 12 hours per day. Individualized TBSI-based enoxaparin dosing regimens and real-time aFXa monitoring deserve further study.

© 2016 American Society of Plastic Surgeons